Document registry — page 19
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low29 Jan 2026 -
Consultation on the draft of CEI-MS-08, which specifies the performance a determination must achieve for chromatographic purity and states what the resulting figure does…
26 Jan 2026 -
To what extent does a change in body weight predict a change in the clinical outcomes for which weight reduction is undertaken?
Low26 Jan 2026 -
Randomised crossover, phase 1 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low26 Jan 2026 -
Consultation on the draft monograph for Mazdutide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
25 Jan 2026 -
Phase 1 ascending dose, phase 1 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low24 Jan 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation…
Moderate23 Jan 2026 -
In the population defined for heart failure with preserved ejection fraction and obesity, what is the incidence of adverse events leading to discontinuation with…
Moderate23 Jan 2026 -
28-residue N-acetylated thymic polypeptide. Thymosin alpha-1 promotes T-lymphocyte differentiation and maturation, increases interleukin-2 and interferon-gamma production, and enhances…
Moderate23 Jan 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Petrelintide compared with the comparator used in its contributing trials on the…
Low19 Jan 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Semaglutide, oral compared with the comparator used in its contributing trials on the…
High18 Jan 2026 -
Observational, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low18 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low18 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over as stated in the parent…
Very low17 Jan 2026 -
Consultation on the draft scoping review of melanocortin receptor agonists, which maps the evidence across approved indications and the uses for which these compounds…
16 Jan 2026 -
Randomised crossover, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low14 Jan 2026 -
Consultation on the draft of this scoping review, which registers the question: What clinical evidence supports the uses under which growth-hormone secretagogues are…
13 Jan 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with CagriSema (cagrilintide with…
Moderate13 Jan 2026 -
In adults with metabolic dysfunction-associated steatohepatitis, do incretin receptor agonists improve histological outcomes, and does histological improvement predict…
Moderate12 Jan 2026 -
Excess adiposity sufficient to impair health, operationalised in the pivotal incretin programmes as a body-mass index of 30 kg/m² or above, or 27 kg/m² or above with at…
12 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity randomising 3,417 participants over 68 weeks. Primary…
Moderate12 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low12 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in sleep apnoea over 52 weeks. The Institute holds no reported primary result for this record…
11 Jan 2026 -
In adolescents with obesity, what is the effect of an incretin receptor agonist on body-mass index, and what is known about growth, bone accrual and pubertal outcomes?
Moderate09 Jan 2026 -
Copper(II)-complexed tripeptide. GHK is a naturally occurring tripeptide present in plasma at concentrations that decline with age. Complexed with copper it acts as a physiological…
Low08 Jan 2026 -
Certificate-of-analysis minimum data standard for synthetic peptide preparations
High08 Jan 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
High07 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low05 Jan 2026 -
Consultation on the draft safety review of delayed gastric emptying and residual gastric content in patients receiving an incretin receptor agonist who present for…
26 Dec 2025 -
Single-arm open-label, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over open-label extension of the parent trial. The…
Very low24 Dec 2025 -
Record of documents ratified in the 2025 Q4 assessment cycle.
22 Dec 2025 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Dec 2025 -
Purity determination for peptides not retained by conventional reverse-phase chromatography
High20 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in knee osteoarthritis and obesity over 68 weeks. Primary result: Improvement relative to…
Low19 Dec 2025 -
Consultation on the draft of this analytical evidence review, which registers the question: What proportion of certificates of analysis supplied with research peptides…
12 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low09 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes randomising 792 participants over 52 weeks…
Moderate08 Dec 2025 -
Genetically determined impairment of oxidative phosphorylation producing myopathy, exercise intolerance or multisystem disease.
07 Dec 2025 -
Small-molecule nicotinamide N-methyltransferase inhibitor. NNMT methylates nicotinamide, diverting it from NAD+ salvage and generating 1-methylnicotinamide. Inhibiting NNMT is proposed to raise cellular NAD+…
Very low07 Dec 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Dec 2025
page 19 of 41